“This acquisition marks a pivotal step in Halozyme’s evolution,” said Helen Torley, Halozyme’s CEO and president. “With Elektrofi’s Hypercon technology, we are broadening our drug delivery portfolio and positioning Halozyme for sustained growth through licensing and royalties.”
Strategic Expansion
The deal significantly bolsters Halozyme’s drug delivery technology pipeline, adding a scalable licensing model with what the company called “compelling expansion opportunities.”
For Elektrofi, the merger represents a chance to supercharge its mission. “Since our founding, we have been committed to revolutionizing the delivery of biologic therapies,” said Chase Coffman, Elektrofi’s CEO and co-founder. “Halozyme’s proven expertise will accelerate our commercialization strategy and help bring Hypercon to more patients worldwide.”
Closing Timeline and Legal Teams
The acquisition is expected to close in the fourth quarter of 2025, subject to regulatory review and customary conditions.
Halozyme is represented by Weil Gotshal & Manges LLP, while Elektrofi is advised by a Morgan Lewis & Bockius LLP team that includes partners Russell Franklin, Mike Conza, and Andrew Haupt.
